The effort will provide individuals with genetic testing to determine if they have the disorder, and when necessary, with genetic testing counselling.
Ambry will offer ArcherDX's immune repertoire sequencing assays to biopharmaceutical customers.
Researchers from Ambry Genetics analyzed a set of DTC results sent to them for confirmation testing and found that 40 percent were false positives.
The partnership will integrate Ambry Genetics' and Invicro's technologies to expedite new drug discovery and development.
Konica Minolta paid $800 million up front for Ambry, with Ambry shareholders eligible to receive up to $200 million in future payments.
The deal will join the AmbryPort 2.0 clinical ordering platform with FDNA's Face2Gene next-generation phenotyping application suite.
Ambry will provide genetic testing in NorthShore’s Genomic Health Initiative in hopes of moving precision medicine into clinical practice.
The company expects the deal will help it launch an immunostaining technology, expand into US pharma services, and establish itself as a genetic testing leader in Japan.
Konica said that the deal represents its first step toward building a presence in the precision medicine field, with an eye toward Japan and then Europe.
Through prospective pancreatic ductal adenocarcinoma testing, researchers saw germline mutations in new genes and in cases outside of current germline testing criteria.
Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.
Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.
In Science this week: research regulation and reporting requirement reform, and more.
With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.